MERS-coronavirus: From discovery to intervention

One Health

Volumn 3, Issue , 2017, Pages 11-16

  Widagdo, W ^a   Okba, Nisreen M A ^a   Stalin Raj, V ^a   Haagmans, Bart L ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Coronavirus; Dromedary camel; Intervention; MERS; Review

Indexed keywords

ADENOSINE DEAMINASE; ALPHA INTERFERON; ANTIVIRUS AGENT; CHLORPROMAZINE; CYCLOSPORIN A; DIPEPTIDYL PEPTIDASE IV; MYCOPHENOLIC ACID; RIBAVIRIN;

DISEASE TRANSMISSION; ENZYME LINKED IMMUNOSORBENT ASSAY; EPIDEMIC; HUMAN; IMMUNOFLUORESCENCE; INFECTION CONTROL; INFECTION PREVENTION; INFECTION SENSITIVITY; LOWER RESPIRATORY TRACT INFECTION; MIDDLE EAST RESPIRATORY SYNDROME; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; MOLECULAR EPIDEMIOLOGY; NONHUMAN; OPEN READING FRAME; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; TROPISM; VACCINATION; VIRUS REPLICATION; VIRUS TITRATION; VIRUS TRANSMISSION;

EID: 85007143704     PISSN: None     EISSN: 23527714     Source Type: Journal    
DOI: 10.1016/j.onehlt.2016.12.001     Document Type: Review

References (88)

1. [1] Zumla, A., Hui, D.S., Perlman, S., Middle East respiratory syndrome. Lancet 386 (2015), 995–1007.
2. [2] Menachery, V.D., Yount, B.L. Jr., Debbink, K., et al. A SARS-like cluster of circulating bat coronaviruses shows potential for human emergence. Nat. Med. 21 (2015), 1508–1513.
3. [3] Zaki, A.M., van Boheemen, S., Bestebroer, T.M., Osterhaus, A.D., Fouchier, R.A., Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N. Engl. J. Med. 367 (2012), 1814–1820.
4. [4] Leung, G.M., Hedley, A.J., Ho, L.M., et al. The epidemiology of severe acute respiratory syndrome in the 2003 Hong Kong epidemic: an analysis of all 1755 patients. Ann. Intern. Med. 141 (2004), 662–673.
5. [5] Drosten, C., Meyer, B., Muller, M.A., et al. Transmission of mers-coronavirus in household contacts. N. Engl. J. Med. 371 (2014), 828–835.
6. OV) in humans. PLoS Curr., 5, 2013.
7. OV) infection: chest CT findings. AJR Am. J. Roentgenol. 203 (2014), 782–787.
8. [8] van Boheemen, S., de Graaf, M., Lauber, C., et al. Genomic characterization of a newly discovered coronavirus associated with acute respiratory distress syndrome in humans. MBio, 3, 2012.
9. [9] Corman, V.M., Eckerle, I., Bleicker, T., et al. Detection of a novel human coronavirus by real-time reverse-transcription polymerase chain reaction. Euro Surveill., 17, 2012.
10. [10] Corman, V.M., Muller, M.A., Costabel, U., et al. Assays for laboratory confirmation of novel human coronavirus (hCoV-EMC) infections. Euro Surveill., 17, 2012.
11. [11] Lu, X., Whitaker, B., Sakthivel, S.K., et al. Real-time reverse transcription-pcr assay panel for Middle East respiratory syndrome coronavirus. J. Clin. Microbiol. 52 (2014), 67–75.
12. [12] Aburizaiza, A.S., Mattes, F.M., Azhar, E.I., et al. Investigation of anti-Middle East respiratory syndrome antibodies in blood donors and slaughterhouse workers in Jeddah and Makkah, Saudi Arabia, fall 2012. J. Infect. Dis. 209 (2014), 243–246.
13. [13] Reusken, C.B., Haagmans, B.L., Muller, M.A., et al. Middle East respiratory syndrome coronavirus neutralising serum antibodies in dromedary camels: a comparative serological study. Lancet Infect. Dis. 13 (2013), 859–866.
14. [14] Alagaili, A.N., Briese, T., Mishra, N., et al. Middle East respiratory syndrome coronavirus infection in dromedary camels in Saudi Arabia. MBio 5 (2014), e00884–e008814.
15. [15] Muller, M.A., Meyer, B., Corman, V.M., et al. Presence of Middle East respiratory syndrome coronavirus antibodies in Saudi Arabia: a nationwide, cross-sectional, serological study. Lancet Infect. Dis. 15 (2015), 559–564.
16. [16] Park, W.B., Perera, R.A., Choe, P.G., et al. Kinetics of serologic responses to mers coronavirus infection in humans, South Korea. Emerg. Infect. Dis. 21 (2015), 2186–2189.
17. [17] Alraddadi, B.M., Watson, J.T., Almarashi, A., et al. Risk factors for primary Middle East respiratory syndrome coronavirus illness in humans, Saudi Arabia, 2014. Emerg. Infect. Dis. 22 (2016), 49–55.
18. [18] de Wilde, A.H., Raj, V.S., Oudshoorn, D., et al. MERS-coronavirus replication induces severe in vitro cytopathology and is strongly inhibited by cyclosporin a or interferon-alpha treatment. J. Gen. Virol. 94 (2013), 1749–1760.
19. [19] Falzarano, D., de Wit, E., Martellaro, C., Callison, J., Munster, V.J., Feldmann, H., Inhibition of novel beta coronavirus replication by a combination of interferon-alpha2b and ribavirin. Sci. Rep., 3, 2013, 1686.
20. [20] Falzarano, D., de Wit, E., Rasmussen, A.L., et al. Treatment with interferon-alpha2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques. Nat. Med. 19 (2013), 1313–1317.
21. [21] Channappanavar, R., Fehr, A.R., Vijay, R., et al. Dysregulated type I interferon and inflammatory monocyte-macrophage responses cause lethal pneumonia in SARS-CoV-infected mice. Cell Host Microbe 19 (2016), 181–193.
22. [22] Smits, S.L., de Lang, A., van den Brand, J.M., et al. Exacerbated innate host response to SARS-CoV in aged non-human primates. PLoS Pathog., 6, 2010, e1000756.
23. [23] Omrani, A.S., Saad, M.M., Baig, K., et al. Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study. Lancet Infect. Dis. 14 (2014), 1090–1095.
24. [24] Hart, B.J., Dyall, J., Postnikova, E., et al. Interferon-beta and mycophenolic acid are potent inhibitors of Middle East respiratory syndrome coronavirus in cell-based assays. J. Gen. Virol. 95 (2014), 571–577.
25. [25] Dyall, J., Coleman, C.M., Hart, B.J., et al. Repurposing of clinically developed drugs for treatment of Middle East respiratory coronavirus infection. Antimicrob. Agents Chemother., 2014.
26. [26] de Wilde, A.H., Jochmans, D., Posthuma, C.C., et al. Screening of an fda-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture. Antimicrob. Agents Chemother., 2014.
27. [27] Zumla, A., Chan, J.F., Azhar, E.I., Hui, D.S., Yuen, K.Y., Coronaviruses — drug discovery and therapeutic options. Nat. Rev. Drug Discov., 2016.
28. [28] Lu, G., Hu, Y., Wang, Q., et al. Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor cd26. Nature 500 (2013), 227–231.
29. [29] Wang, N., Shi, X., Jiang, L., et al. Structure of MERS-CoV spike receptor-binding domain complexed with human receptor dpp4. Cell Res. 23 (2013), 986–993.
30. [30] Chen, Y., Rajashankar, K.R., Yang, Y., et al. Crystal structure of the receptor-binding domain from newly emerged Middle East respiratory syndrome coronavirus. J. Virol. 87 (2013), 10777–10783.
31. [31] Raj, V.S., Mou, H., Smits, S.L., et al. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature 495 (2013), 251–254.
32. [32] Gao, J., Lu, G., Qi, J., et al. Structure of the fusion core and inhibition of fusion by a heptad repeat peptide derived from the S protein of Middle East respiratory syndrome coronavirus. J. Virol. 87 (2013), 13134–13140.
33. [33] Lu, L., Liu, Q., Zhu, Y., et al. Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor. Nat. Commun., 5, 2014, 3067.
34. [34] Lundin, A., Dijkman, R., Bergstrom, T., et al. Targeting membrane-bound viral RNA synthesis reveals potent inhibition of diverse coronaviruses including the Middle East respiratory syndrome virus. PLoS Pathog., 10, 2014, e1004166.
35. [35] Adedeji, A.O., Singh, K., Kassim, A., et al. Evaluation of SSYA10-001 as a replication inhibitor of SARS, MHV and MERS coronaviruses. Antimicrob. Agents Chemother., 2014.
36. [36] Memish, Z.A., Al-Tawfiq, J.A., Makhdoom, H.Q., et al. Screening for Middle East respiratory syndrome coronavirus infection in hospital patients and their healthcare worker and family contacts: a prospective descriptive study. Clin. Microbiol. Infect. 20 (2014), 469–474.
37. [37] Park, G.E., Ko, J.H., Peck, K.R., et al. Control of an outbreak of Middle East respiratory syndrome in a tertiary hospital in Korea. Ann. Intern. Med. 165 (2016), 87–93.
38. [38] Ng, D.L., Al Hosani, F., Keating, M.K., et al. Clinicopathologic, immunohistochemical, and ultrastructural findings of a fatal case of Middle East respiratory syndrome coronavirus infection in the United Arab Emirates, april 2014. Am. J. Pathol. 186 (2016), 652–658.
39. [39] Hocke, A.C., Becher, A., Knepper, J., et al. Emerging human Middle East respiratory syndrome coronavirus causes widespread infection and alveolar damage in human lungs. Am. J. Respir. Crit. Care Med. 188 (2013), 882–886.
40. [40] Bermingham, A., Chand, M.A., Brown, C.S., et al. Severe respiratory illness caused by a novel coronavirus, in a patient transferred to the United Kingdom from the Middle East, September 2012. Euro Surveill., 17, 2012, 20290.
41. [41] Drosten, C., Seilmaier, M., Corman, V.M., et al. Clinical features and virological analysis of a case of Middle East respiratory syndrome coronavirus infection. Lancet Infect. Dis. 13 (2013), 745–751.
42. [42] Corman, V.M., Albarrak, A.M., Omrani, A.S., et al. Viral shedding and antibody response in 37 patients with Middle East respiratory syndrome coronavirus infection. Clin. Infect. Dis. 62 (2016), 477–483.
43. [43] Widagdo, W., Raj, V.S., Schipper, D., et al. Differential expression of the MERS-coronavirus receptor in the upper respiratory tract of humans and dromedary camels. J. Virol., 2016.
44. [44] Al-Abdallat, M.M., Payne, D.C., Alqasrawi, S., et al. Hospital-associated outbreak of Middle East respiratory syndrome coronavirus: a serologic, epidemiologic, and clinical description. Clin. Infect. Dis. 59 (2014), 1225–1233.
45. [45] Assiri, A., McGeer, A., Perl, T.M., et al. Hospital outbreak of Middle East respiratory syndrome coronavirus. N. Engl. J. Med. 369 (2013), 407–416.
46. [46] Reusken, C.B., Farag, E.A., Haagmans, B.L., et al. Occupational exposure to dromedaries and risk for MERS-CoV infection, Qatar, 2013–2014. Emerg. Infect. Dis. 21 (2015), 1422–1425.
47. [47] Haagmans, B.L., Al Dhahiry, S.H., Reusken, C.B., et al. Middle East respiratory syndrome coronavirus in dromedary camels: an outbreak investigation. Lancet Infect. Dis. 14 (2014), 140–145.
48. [48] Cauchemez, S., Nouvellet, P., Cori, A., et al. Unraveling the drivers of MERS-CoV transmission. Proc. Natl. Acad. Sci. U. S. A. 113 (2016), 9081–9086.
49. [49] Rainer, T.H., Chan, P.K., Ip, M., et al. The spectrum of severe acute respiratory syndrome-associated coronavirus infection. Ann. Intern. Med. 140 (2004), 614–619.
50. [50] Leung, G.M., Chung, P.H., Tsang, T., et al. SARS-CoV antibody prevalence in all Hong Kong patient contacts. Emerg. Infect. Dis. 10 (2004), 1653–1656.
51. [51] Oh, M.D., Park, W.B., Choe, P.G., et al. Viral load kinetics of MERS coronavirus infection. N. Engl. J. Med. 375 (2016), 1303–1305.
52. [52] Al-Gethamy, M., Corman, V.M., Hussain, R., Al-Tawfiq, J.A., Drosten, C., Memish, Z.A., A case of long-term excretion and subclinical infection with Middle East respiratory syndrome coronavirus in a healthcare worker. Clin. Infect. Dis. 60 (2015), 973–974.
53. [53] Haagmans, B.L., Osterhaus, A.D., Neutralizing the MERS coronavirus threat. Sci. Transl. Med., 6, 2014, 235fs219.
54. [54] Tang, X.C., Agnihothram, S.S., Jiao, Y., et al. Identification of human neutralizing antibodies against MERS-CoV and their role in virus adaptive evolution. Proc. Natl. Acad. Sci. U. S. A. 111 (2014), E2018–E2026.
55. [55] Ying, T., Du, L., Ju, T.W., et al. Exceptionally potent neutralization of MERS-CoV by human monoclonal antibodies. J. Virol., 2014.
56. [56] Jiang, L., Wang, N., Zuo, T., et al. Potent neutralization of MERS-CoV by human neutralizing monoclonal antibodies to the viral spike glycoprotein. Sci. Transl. Med., 6, 2014, 234ra259.
57. [57] Corti, D., Zhao, J., Pedotti, M., et al. Prophylactic and postexposure efficacy of a potent human monoclonal antibody against MERS coronavirus. Proc. Natl. Acad. Sci. U. S. A. 112 (2015), 10473–10478.
58. [58] Li, Y., Wan, Y., Liu, P., et al. A humanized neutralizing antibody against MERS-CoV targeting the receptor-binding domain of the spike protein. Cell Res. 25 (2015), 1237–1249.
59. [59] Du, L., Kou, Z., Ma, C., et al. A truncated receptor-binding domain of MERS-CoV spike protein potently inhibits MERS-CoV infection and induces strong neutralizing antibody responses: implication for developing therapeutics and vaccines. PLoS One, 8, 2013, e81587.
60. [60] Houser, K.V., Gretebeck, L., Ying, T., et al. Prophylaxis with a Middle East respiratory syndrome coronavirus (MERS-CoV)-specific human monoclonal antibody protects rabbits from MERS-CoV infection. J. Infect. Dis., 2016.
61. [61] Ohnuma, K., Haagmans, B.L., Hatano, R., et al. Inhibition of Middle East respiratory syndrome coronavirus infection by anti-cd26 monoclonal antibody. J. Virol. 87 (2013), 13892–13899.
62. [62] Lee, V.J., Yap, J., Cook, A.R., et al. Oseltamivir ring prophylaxis for containment of 2009 H1N1 influenza outbreaks. N. Engl. J. Med. 362 (2010), 2166–2174.
63. [63] Zhao, J., Wohlford-Lenane, C., Zhao, J., et al. Intranasal treatment with poly(i*c) protects aged mice from lethal respiratory virus infections. J. Virol. 86 (2012), 11416–11424.
64. [64] Volz, A., Kupke, A., Song, F., et al. Protective efficacy of recombinant modified vaccinia virus Ankara delivering Middle East respiratory syndrome coronavirus spike glycoprotein. J. Virol. 89 (2015), 8651–8656.
65. [65] Kreijtz, J.H., Goeijenbier, M., Moesker, F.M., et al. Safety and immunogenicity of a modified-vaccinia-virus-Ankara-based influenza a H5N1 vaccine: a randomised, double-blind phase 1/2a clinical trial. Lancet Infect. Dis. 14 (2014), 1196–1207.
66. [66] Reusken, C.B., Ababneh, M., Raj, V.S., et al. Middle East respiratory syndrome coronavirus (MERS-CoV) serology in major livestock species in an affected region in Jordan, June to September 2013. Euro Surveill., 18, 2013, 20662.
67. [67] Hemida, M.G., Perera, R.A., Wang, P., et al. Middle East Respiratory Syndrome (MERS) coronavirus seroprevalence in domestic livestock in Saudi Arabia, 2010 to 2013. Euro Surveill., 18, 2013, 20659.
68. [68] Hemida, M.G., Perera, R.A., Al Jassim, R.A., et al. Seroepidemiology of Middle East respiratory syndrome (MERS) coronavirus in Saudi Arabia (1993) and Australia (2014) and characterisation of assay specificity. Euro Surveill., 19, 2014.
69. [69] Chu, D.K., Oladipo, J.O., Perera, R.A., et al. Middle East respiratory syndrome coronavirus (MERS-CoV) in dromedary camels in Nigeria, 2015. Euro Surveill., 20, 2015.
70. [70] Corman, V.M., Jores, J., Meyer, B., et al. Antibodies against MERS coronavirus in dromedary camels, Kenya, 1992–2013. Emerg. Infect. Dis. 20 (2014), 1319–1322.
71. [71] Reusken, C.B., Messadi, L., Feyisa, A., et al. Geographic distribution of MERS coronavirus among dromedary camels, Africa. Emerg. Infect. Dis. 20 (2014), 1370–1374.
72. [72] Muller, M.A., Corman, V.M., Jores, J., et al. MERS coronavirus neutralizing antibodies in camels, Eastern Africa, 1983–1997. Emerg. Infect. Dis. 20 (2014), 2093–2095.
73. [73] Raj, V.S., Farag, E.A., Reusken, C.B., et al. Isolation of MERS coronavirus from a dromedary camel, Qatar, 2014. Emerg. Infect. Dis. 20 (2014), 1339–1342.
74. [74] Khalafalla, A.I., Lu, X., Al-Mubarak, A.I., Dalab, A.H., Al-Busadah, K.A., Erdman, D.D., MERS-CoV in upper respiratory tract and lungs of dromedary camels, Saudi Arabia, 2013–2014. Emerg. Infect. Dis. 21 (2015), 1153–1158.
75. [75] Adney, D.R., van Doremalen, N., Brown, V.R., et al. Replication and shedding of MERS-CoV in upper respiratory tract of inoculated dromedary camels. Emerg. Infect. Dis. 20 (2014), 1999–2005.
76. [76] Haagmans, B.L., van den Brand, J.M., Raj, V.S., et al. An orthopoxvirus-based vaccine reduces virus excretion after MERS-CoV infection in dromedary camels. Science 351 (2016), 77–81.
77. [77] Memish, Z.A., Cotten, M., Meyer, B., et al. Human infection with MERS coronavirus after exposure to infected camels, Saudi Arabia, 2013. Emerg. Infect. Dis. 20 (2014), 1012–1015.
78. [78] Liljander, A., Meyer, B., Jores, J., et al. MERS-CoV antibodies in humans, Africa, 2013–2014. Emerg. Infect. Dis. 22 (2016), 1086–1089.
79. [79] Barlan, A., Zhao, J., Sarkar, M.K., et al. Receptor variation and susceptibility to Middle East respiratory syndrome coronavirus infection. J. Virol. 88 (2014), 4953–4961.
80. [80] van Doremalen, N., Miazgowicz, K.L., Milne-Price, S., et al. Host species restriction of Middle East respiratory syndrome coronavirus through its receptor, dipeptidyl peptidase 4. J. Virol. 88 (2014), 9220–9232.
81. [81] Meyer, B., Garcia-Bocanegra, I., Wernery, U., et al. Serologic assessment of possibility for MERS-CoV infection in equids. Emerg. Infect. Dis. 21 (2015), 181–182.
82. [82] Crameri, G., Durr, P.A., Klein, R., et al. Experimental infection and response to rechallenge of alpacas with Middle East respiratory syndrome coronavirus. Emerg. Infect. Dis., 22, 2016.
83. [83] Adney, D.R., Bielefeldt-Ohmann, H., Hartwig, A.E., Bowen, R.A., Infection, replication, and transmission of Middle East respiratory syndrome coronavirus in alpacas. Emerg. Infect. Dis. 22 (2016), 1031–1037.
84. [84] Reusken, C.B., Schilp, C., Raj, V.S., et al. MERS-CoV infection of alpaca in a region where MERS-CoV is endemic. Emerg. Infect. Dis., 22, 2016.
85. [85] Vergara-Alert, J., van den Brand, J.M., Widagdo, W., et al. Susceptibility of different livestock animal species for Middle East respiratory syndrome coronavirus infection. Emerg. Infect. Dis., 2016 (in press. EID-16-1239.R1).
86. [86] Adney, D.R., Brown, V.R., Porter, S.M., Bielefeldt-Ohmann, H., Hartwig, A.E., Bowen, R.A., Inoculation of goats, sheep, and horses with MERS-CoV does not result in productive viral shedding. Viruses, 8, 2016.
87. [87] Watts, J., China culls wild animals to prevent new SARS threat. Lancet, 363, 2004, 134.
88. [88] Meyer, B., Juhasz, J., Barua, R., et al. Time course of MERS-CoV infection and immunity in dromedary camels. Emerg. Infect. Dis. 22 (2016), 2171–2173.